With high NHS waiting lists due to the impact of COVID-19 on services, the OmniLenz family was expanded to offer an effective alternative for healthcare professionals to reduce the requirement for scheduled surgery.
Please see www.nu-vision.co.uk/omnilenz for more information on OmniLenz.
NuVision Biotherapies
Based in MediCity, Nottingham, NuVision Biotherapies is a biotechnology company recently spun out from Academic Ophthalmology, School of Medicine, University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge, regenerative therapies.
About Omnigen
Omnigen is a patented, dry preparation of human-derived amniotic membrane, made from the sac surrounding the baby during pregnancy. The Tereo® manufacturing process, developed over 18 years at the University of Nottingham Ophthalmology department, transforms this waste product of birth into an aseptically processed and stable dry transplant product. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial barrier function to aid and support natural healing in a variety of ways. The product represents a unique and versatile “off-the-shelf” product and may be stored long term. The Tereo process preserves the natural barrier function of the amniotic membrane and provides surgeons with an effective sight saving bandage that could provide a meaningful support to patients, suffering from ocular surface disorders with unmet medical need.
About OmniLenz
OmniLenz is a bandage contact lens specially designed to apply and hold Omnigen on the ocular surface without the need for sutures or surgery. OmniLenz is manufactured for exclusively for NuVision by Menicon UK. OmniLenz can be applied in a simple 4 – 6 minute procedure in an outpatient setting.
Continue reading:
www.nu-vision.co.uk
